HOWL

Werewolf Therapeutics (HOWL)

About Werewolf Therapeutics (HOWL)

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Details

Daily high

$1.14

Daily low

$1.06

Price at open

$1.12

52 Week High

$5.73

52 Week Low

$0.60

Market cap

49.8M

Dividend yield

0.00%

Volume

425,253

Avg. volume

362,558

P/E ratio

-.68

Werewolf Therapeutics News